1. Home
  2. CTRM vs PLUR Comparison

CTRM vs PLUR Comparison

Compare CTRM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.44

Market Cap

21.6M

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$1.75

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
PLUR
Founded
2016
2001
Country
Cyprus
Israel
Employees
N/A
142
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
18.5M
IPO Year
2017
2001

Fundamental Metrics

Financial Performance
Metric
CTRM
PLUR
Price
$2.44
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
34.1K
15.9K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
N/A
$1,336,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
N/A
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$1.66
$1.45
52 Week High
$2.65
$5.48

Technical Indicators

Market Signals
Indicator
CTRM
PLUR
Relative Strength Index (RSI) 70.02 47.81
Support Level $2.01 $1.56
Resistance Level $2.65 $1.86
Average True Range (ATR) 0.12 0.10
MACD 0.04 0.02
Stochastic Oscillator 100.00 56.43

Price Performance

Historical Comparison
CTRM
PLUR

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: